{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:09:19Z","timestamp":1791950959195,"version":"4.3.4"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Ministry of Science and ICT, South Korea","doi-asserted-by":"publisher","award":["RS-2024\\u201300441331"],"award-info":[{"award-number":["RS-2024\\u201300441331"]}],"id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain, Behavior, and Immunity"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.bbi.2025.06.001","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T11:32:38Z","timestamp":1749209558000},"page":"196-205","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["A Novel A\u03b2 B-cell epitope Vaccine, A\u03b21-10 with carrier protein OVA and KLH reduce A\u03b2-induced neuroinflammation mediated neuropathology in mouse model of Alzheimer\u2019s disease"],"prefix":"10.1016","volume":"129","author":[{"given":"Jun Sung","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyonghwan","family":"Choe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riaz","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Hwa","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Ju","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myeong Ok","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bbi.2025.06.001_b0005","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jalz.2016.03.001","article-title":"2016 Alzheimer's disease facts and figures","volume":"12","author":"Alzheimer's","year":"2016","journal-title":"Alzheimers Dement."},{"issue":"4","key":"10.1016\/j.bbi.2025.06.001_b0010","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/0896-6273(91)90052-2","article-title":"The molecular pathology of Alzheimer's disease","volume":"6","author":"Selkoe","year":"1991","journal-title":"Neuron."},{"issue":"5","key":"10.1016\/j.bbi.2025.06.001_b0015","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/00005072-199409000-00003","article-title":"Alzheimer's disease: a central role for amyloid","volume":"53","author":"Selkoe","year":"1994","journal-title":"J Neuropathol Exp Neurol."},{"issue":"2","key":"10.1016\/j.bbi.2025.06.001_b0020","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrm2101","article-title":"Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide","volume":"8","author":"Haass","year":"2007","journal-title":"Nat Rev Mol Cell Biol."},{"issue":"1","key":"10.1016\/j.bbi.2025.06.001_b0025","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nn1372","article-title":"Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function","volume":"8","author":"Cleary","year":"2005","journal-title":"Nat Neurosci."},{"issue":"5","key":"10.1016\/j.bbi.2025.06.001_b0030","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.neurobiolaging.2004.02.010","article-title":"Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease","volume":"25","author":"Klein","year":"2004","journal-title":"Neurobiol Aging."},{"issue":"2","key":"10.1016\/j.bbi.2025.06.001_b0035","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41582-018-0116-6","article-title":"A critical appraisal of amyloid-beta-targeting therapies for Alzheimer disease","volume":"15","author":"Panza","year":"2019","journal-title":"Nat Rev Neurol."},{"issue":"6012","key":"10.1016\/j.bbi.2025.06.001_b0040","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1126\/science.1197623","article-title":"Decreased clearance of CNS beta-amyloid in Alzheimer's disease","volume":"330","author":"Mawuenyega","year":"2010","journal-title":"Science."},{"issue":"1","key":"10.1016\/j.bbi.2025.06.001_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1192\/bjp.bp.115.167569","article-title":"Alzheimer's disease: the amyloid hypothesis on trial","volume":"208","author":"Harrison","year":"2016","journal-title":"Br J Psychiatry."},{"issue":"4","key":"10.1016\/j.bbi.2025.06.001_b0050","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research framework: Toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement."},{"issue":"6740","key":"10.1016\/j.bbi.2025.06.001_b0055","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature."},{"issue":"28","key":"10.1016\/j.bbi.2025.06.001_b0060","doi-asserted-by":"crossref","first-page":"6277","DOI":"10.1523\/JNEUROSCI.1344-04.2004","article-title":"An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives","volume":"24","author":"Sigurdsson","year":"2004","journal-title":"J Neurosci."},{"key":"10.1016\/j.bbi.2025.06.001_b0065","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1741-7015-7-7","article-title":"Recent developments in Alzheimer's disease therapeutics","volume":"7","author":"Rafii","year":"2009","journal-title":"BMC Med."},{"key":"10.1016\/j.bbi.2025.06.001_b0070","article-title":"Alzheimer's disease: the challenge of the second century","volume":"3(77):77sr1","author":"Holtzman","year":"2011","journal-title":"Sci Transl Med."},{"key":"10.1016\/j.bbi.2025.06.001_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.105010","article-title":"Passive immunotherapies targeting abeta and tau in Alzheimer's disease","volume":"144","author":"Plotkin","year":"2020","journal-title":"Neurobiol Dis."},{"issue":"3","key":"10.1016\/j.bbi.2025.06.001_b0080","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/21645515.2019.1665453","article-title":"Rationale for the development of an Alzheimer's disease vaccine","volume":"16","author":"Kwan","year":"2020","journal-title":"Hum Vaccin Immunother."},{"issue":"1","key":"10.1016\/j.bbi.2025.06.001_b0085","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1365-2796.2010.02315.x","article-title":"Immunotherapy for Alzheimer's disease","volume":"269","author":"Morgan","year":"2011","journal-title":"J Intern Med."},{"issue":"2","key":"10.1016\/j.bbi.2025.06.001_b0090","doi-asserted-by":"crossref","first-page":"128","DOI":"10.2174\/187152709787847298","article-title":"Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy","volume":"8","author":"Ghochikyan","year":"2009","journal-title":"CNS Neurol Disord Drug Targets."},{"issue":"17","key":"10.1016\/j.bbi.2025.06.001_b0095","doi-asserted-by":"crossref","first-page":"3260","DOI":"10.1016\/j.vaccine.2011.02.026","article-title":"Identification of the shortest abeta-peptide generating highly specific antibodies against the C-terminal end of amyloid-beta42","volume":"29","author":"Axelsen","year":"2011","journal-title":"Vaccine."},{"issue":"9","key":"10.1016\/j.bbi.2025.06.001_b0100","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of abeta immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology."},{"issue":"11","key":"10.1016\/j.bbi.2025.06.001_b0105","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/nm790","article-title":"Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis","volume":"8","author":"McLaurin","year":"2002","journal-title":"Nat Med."},{"key":"10.1016\/j.bbi.2025.06.001_b0110","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/srep00480","article-title":"Hypothermia-induced hyperphosphorylation: a new model to study tau kinase inhibitors","volume":"2","author":"Bretteville","year":"2012","journal-title":"Sci Rep."},{"issue":"2","key":"10.1016\/j.bbi.2025.06.001_b0115","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ajpath.2015.10.010","article-title":"Plaque-associated local toxicity increases over the clinical course of Alzheimer disease","volume":"186","author":"Serrano-Pozo","year":"2016","journal-title":"Am J Pathol."},{"issue":"10","key":"10.1016\/j.bbi.2025.06.001_b0120","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1523\/JNEUROSCI.3710-06.2007","article-title":"Active beta-amyloid immunization restores spatial learning in PDAPP mice displaying very low levels of beta-amyloid","volume":"27","author":"Chen","year":"2007","journal-title":"J Neurosci."},{"issue":"2","key":"10.1016\/j.bbi.2025.06.001_b0125","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1536\/ihj.13-383","article-title":"Therapeutic vaccines for hypertension and dyslipidemia","volume":"55","author":"Nakagami","year":"2014","journal-title":"Int Heart J."},{"issue":"2","key":"10.1016\/j.bbi.2025.06.001_b0130","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201910919","article-title":"Active poly-GA vaccination prevents microglia activation and motor deficits in a C9orf72 mouse model","volume":"12","author":"Zhou","year":"2020","journal-title":"EMBO Mol Med."},{"key":"10.1016\/j.bbi.2025.06.001_b0135","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/978-1-4939-2999-3_25","article-title":"Prion-specific antibodies produced in wild-type mice","volume":"1348","author":"Heegaard","year":"2015","journal-title":"Methods Mol Biol."},{"issue":"s1","key":"10.1016\/j.bbi.2025.06.001_b0140","doi-asserted-by":"crossref","first-page":"S567","DOI":"10.3233\/JAD-179941","article-title":"The amyloid-beta Oligomer hypothesis: beginning of the third decade","volume":"64","author":"Cline","year":"2018","journal-title":"J Alzheimers Dis."},{"issue":"2","key":"10.1016\/j.bbi.2025.06.001_b0145","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00702-017-1820-x","article-title":"Amyloid beta oligomers (AbetaOs) in Alzheimer's disease","volume":"125","author":"Mroczko","year":"2018","journal-title":"J Neural Transm (vienna)."},{"key":"10.1016\/j.bbi.2025.06.001_b0150","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0079-6123(09)17506-4","article-title":"Developing novel immunogens for a safe and effective Alzheimer's disease vaccine","volume":"175","author":"Lemere","year":"2009","journal-title":"Prog Brain Res."},{"issue":"5440","key":"10.1016\/j.bbi.2025.06.001_b0155","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1126\/science.286.5440.735","article-title":"Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE","volume":"286","author":"Vassar","year":"1999","journal-title":"Science."},{"issue":"2","key":"10.1016\/j.bbi.2025.06.001_b0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0171925","article-title":"alpha-synuclein increases beta-amyloid secretion by promoting beta-\/gamma-secretase processing of APP","volume":"12","author":"Roberts","year":"2017","journal-title":"PLoS One."},{"issue":"15","key":"10.1016\/j.bbi.2025.06.001_b0165","doi-asserted-by":"crossref","first-page":"10873","DOI":"10.1074\/jbc.M608856200","article-title":"Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation","volume":"282","author":"Zhang","year":"2007","journal-title":"J Biol Chem."},{"issue":"3","key":"10.1016\/j.bbi.2025.06.001_b0170","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1006\/nbdi.2002.0515","article-title":"Oxidative stress increases expression and activity of BACE in NT2 neurons","volume":"10","author":"Tamagno","year":"2002","journal-title":"Neurobiol Dis."},{"issue":"4","key":"10.1016\/j.bbi.2025.06.001_b0175","doi-asserted-by":"crossref","first-page":"871","DOI":"10.3233\/JAD-2011-110884","article-title":"Amyloid-beta(4)(2) activates the expression of BACE1 through the JNK pathway","volume":"27","author":"Guglielmotto","year":"2011","journal-title":"J Alzheimers Dis."},{"issue":"5","key":"10.1016\/j.bbi.2025.06.001_b0180","doi-asserted-by":"crossref","DOI":"10.3390\/cells8050474","article-title":"pHluorin-BACE1-mCherry acts as a reporter for the Intracellular distribution of active BACE1 in vitro and in vivo","volume":"8","author":"Zhao","year":"2019","journal-title":"Cells."},{"issue":"10","key":"10.1016\/j.bbi.2025.06.001_b0185","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s40266-016-0406-x","article-title":"Antibody-based drugs and approaches against amyloid-beta species for Alzheimer's disease immunotherapy","volume":"33","author":"Liu","year":"2016","journal-title":"Drugs Aging."},{"key":"10.1016\/j.bbi.2025.06.001_b0190","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.neures.2017.01.003","article-title":"Prophylactic active immunization with a novel epitope vaccine improves cognitive ability by decreasing amyloid plaques and neuroinflammation in APP\/PS1 transgenic mice","volume":"119","author":"Ding","year":"2017","journal-title":"Neurosci Res."},{"key":"10.1016\/j.bbi.2025.06.001_b0195","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.brainresbull.2021.05.019","article-title":"Immunization with Abeta3-10-KLH vaccine improves cognitive function and ameliorates mitochondrial dysfunction and reduces Alzheimer's disease-like pathology in tg-APPswe\/PSEN1dE9 mice","volume":"174","author":"Zhang","year":"2021","journal-title":"Brain Res Bull."},{"key":"10.1016\/j.bbi.2025.06.001_b0200","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.bbr.2017.05.056","article-title":"Immunization of tg-APPswe\/PSEN1dE9 mice with Abeta3-10-KLH vaccine prevents synaptic deficits of Alzheimer's disease","volume":"332","author":"Meng","year":"2017","journal-title":"Behav Brain Res."},{"issue":"2","key":"10.1016\/j.bbi.2025.06.001_b0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149451","article-title":"MW151 inhibited IL-1\u03b2 levels after traumatic brain injury with no effect on microglia physiological responses","volume":"11","author":"Bachstetter","year":"2016","journal-title":"PLoS One."},{"issue":"3","key":"10.1016\/j.bbi.2025.06.001_b0210","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1007\/s12035-016-9795-4","article-title":"Neuroprotective effect of fisetin against amyloid-Beta-induced cognitive\/synaptic dysfunction, neuroinflammation, and neurodegeneration in adult mice","volume":"54","author":"Ahmad","year":"2017","journal-title":"Mol Neurobiol."},{"issue":"1","key":"10.1016\/j.bbi.2025.06.001_b0215","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/glia.22581","article-title":"High mobility group box protein-1 promotes cerebral edema after traumatic brain injury via activation of toll-like receptor 4","volume":"62","author":"Laird","year":"2014","journal-title":"Glia."},{"key":"10.1016\/j.bbi.2025.06.001_b0220","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.740939","article-title":"Traumatic brain injury: mechanisms of Glial response","volume":"12","author":"Mira","year":"2021","journal-title":"Front Physiol."},{"issue":"7638","key":"10.1016\/j.bbi.2025.06.001_b0225","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature21029","article-title":"Neurotoxic reactive astrocytes are induced by activated microglia","volume":"541","author":"Liddelow","year":"2017","journal-title":"Nature."},{"issue":"5","key":"10.1016\/j.bbi.2025.06.001_b0230","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.neuron.2006.10.035","article-title":"AMPAR removal underlies abeta-induced synaptic depression and dendritic spine loss","volume":"52","author":"Hsieh","year":"2006","journal-title":"Neuron."},{"key":"10.1016\/j.bbi.2025.06.001_b0235","doi-asserted-by":"crossref","first-page":"11708","DOI":"10.1038\/srep11708","article-title":"Osmotin attenuates amyloid beta-induced memory impairment, tau phosphorylation and neurodegeneration in the mouse hippocampus","volume":"5","author":"Ali","year":"2015","journal-title":"Sci Rep."},{"issue":"10","key":"10.1016\/j.bbi.2025.06.001_b0240","doi-asserted-by":"crossref","first-page":"5127","DOI":"10.1007\/s12035-021-02460-4","article-title":"Antioxidative and anti-inflammatory effects of kojic acid in abeta-induced mouse model of Alzheimer's disease","volume":"58","author":"Khan","year":"2021","journal-title":"Mol Neurobiol."},{"issue":"22","key":"10.1016\/j.bbi.2025.06.001_b0245","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20225789","article-title":"Connexin43 is required for the effective activation of spleen cells and immunoglobulin production","volume":"20","author":"Huang","year":"2019","journal-title":"Int J Mol Sci."},{"issue":"2","key":"10.1016\/j.bbi.2025.06.001_b0250","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s12185-020-02912-y","article-title":"The human spleen as the center of the blood defense system","volume":"112","author":"Kashimura","year":"2020","journal-title":"Int J Hematol."}],"container-title":["Brain, Behavior, and Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889159125002089?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889159125002089?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T20:48:14Z","timestamp":1759610894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889159125002089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":50,"alternative-id":["S0889159125002089"],"URL":"https:\/\/doi.org\/10.1016\/j.bbi.2025.06.001","relation":{},"ISSN":["0889-1591"],"issn-type":[{"value":"0889-1591","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Novel A\u03b2 B-cell epitope Vaccine, A\u03b21-10 with carrier protein OVA and KLH reduce A\u03b2-induced neuroinflammation mediated neuropathology in mouse model of Alzheimer\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Brain, Behavior, and Immunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbi.2025.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}